Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pediatric Advisory Committee says the easiest short-term remedy for improving the quality of the agency’s adverse event reporting system would be claims database analysis, although the best method would be population-based active surveillance.
You may also be interested in...
FDA Adding More Pediatric Data To Labeling
FDA divisions will be more aggressive in requiring pediatric data be included in labeling following recommendation by Office of New Drugs Director Jenkins. However, the added language in labeling will not necessarily clarify whether a drug is safe for use in children, Office of Pediatric Therapeutics Director Murphy notes.
Lotensin, Xenical, Brevibloc Need Continued Pediatric AE Monitoring – Committee
FDA's Pediatric Advisory Committee recommends continued monitoring for an additional year of pediatric adverse events associated with Novartis' anti-hypertensive Lotensin
FDA Adding More Pediatric Data To Labeling
FDA divisions will be more aggressive in requiring pediatric data be included in labeling following recommendation by Office of New Drugs Director Jenkins. However, the added language in labeling will not necessarily clarify whether a drug is safe for use in children, Office of Pediatric Therapeutics Director Murphy notes.